Could a pill stop Alzheimer's before it starts? new trial targets High-Risk gene carriers
NCT ID NCT07399171
First seen Feb 12, 2026 · Last updated Jun 19, 2026 · Updated 18 times
Summary
This study tests an experimental drug, HT-4253, to see if it can lower the risk of Alzheimer's disease in people who carry the APOE4 gene and have early signs of brain changes. About 112 adults aged 50-75 with no memory problems but a high-risk blood test result will take the drug or a placebo for 48 weeks. The goal is to move participants from a high-risk to a low-risk score on a specialized blood test that measures Alzheimer's-related proteins.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMERS DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cleveland Clinic Abu Dhabi
Abu Dhabi, United Arab Emirates
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.